Amyotrophic lateral sclerosis (ALS) is a devastating adult-onset progressive neurodegenerative disease characterized by upper and lower motoneuron degeneration. A total of 20% of familial ALS (fALS) cases are explained by mutations in the superoxide dismutase 1 (SOD1) enzyme. Although more than 20 years have passed since the generation of the first ALS mouse model, the precise molecular mechanisms of ALS pathogenesis remain unknown. CTGF/CCN2 is a matricellular protein with associated fibrotic activity that is up-regulated in several chronic diseases. The inhibition of CTGF/CCN2 with the monoclonal neutralizing antibody FG-3019 reduces fibrosis in several chronic disorders including the mdx mice, a murine model for Duchenne muscular dystrophy (DMD). In this work, we show that there are increased levels of CTGF/CCN2 in skeletal muscle and spinal cord of hSOD1 G93A mice. In this scenario, we show evidence that FG-3019 not only reduces fibrosis in skeletal muscle of hSOD1 G93A mice, but also improves muscle and locomotor performance. We demonstrate that treatment with FG-3019 reduces muscle atrophy in hSOD1 G93A mice. We also found improvement of neuromuscular junction (NMJ) innervation together with a reduction in myelin degeneration in the sciatic nerve, suggesting that alterations in nerve-muscle communication are partially improved in FG-3019-treated hSOD1 G93A mice. Moreover, we also found that CTGF/CCN2 is expressed in astrocytes and neurons, predominantly in dorsal areas of spinal cord from symptomatic hSOD1 G93A mice. Together, these results reveal that CTGF/CCN2 might be a novel therapeutic target to ameliorate symptoms and improve the quality of life of ALS patients.
Introduction
Amyotrophic lateral sclerosis (ALS) is a fatal adult-onset neurodegenerative disease characterized by the degeneration of motoneurons in the motor cortex, brainstem and spinal cord. This loss of motoneurons leads to skeletal muscle wasting, fibrosis, paralysis and eventually death from respiratory failure within 3-5 years of diagnosis (1) (2) (3) . About 10% of ALS cases are familial (fALS), with an associated genetic component and usually with dominant inheritance. The superoxide dismutase 1 gene (SOD1) was the first one to be linked to ALS and it accounts for about 20% of fALS cases. Although more than 20 years have passed since generation of the first ALS mouse model (hSOD1 G93A ), the exact mechanisms by which SOD1 exerts its toxic effects remain unclear. Besides the SOD1 gene, a hexanucleotide repeat expansion GGGGCC in the C9orf72 gene has also been linked to ALS, and accounts for $50% of fALS cases (4, 5) . To date, Riluzole and Radicava (edaravone) are the only two FDA-approved drugs for the treatment of ALS; however, Riluzole has limited therapeutic benefits, extending the patients' life expectancy by only a few months (6) . Radicava seems to be more effective in earlier stages of the disease (7, 8) . Thus, identification of new therapeutic targets is urgently needed.
To date, it has not been well established whether skeletal muscle contributes to degeneration of motoneurons and disease progression. There is evidence showing that restricted expression of SOD1 G93A in skeletal muscle is sufficient to induce the characteristic ALS phenotype (9, 10) , indicating that this tissue is a primary target of SOD1 G93A toxicity. However, the molecular mechanisms involved remain obscure. Fibrosis is a common feature underlying several chronic disorders and involves the replacement of functional tissue by non-functional connective tissue composed of extracellular matrix (ECM) molecules such as proteoglycans, fibronectin and different types of collagens (11) (12) (13) . The fibrotic process is well described in several chronic disorders including liver disease, idiopathic pulmonary fibrosis, heart failure and skeletal muscle dystrophies (14) (15) (16) (17) .
Connective tissue growth factor (CTGF/CCN2) is a matricellular protein containing four domains: domain 1, homologous to IGF-1 binding proteins; domain 2, homologous to von Willbrand factor type C repeat; domain 3, homologous to thrombospondin type 1 repeat; and domain 4, which contains a cysteine knot motif that binds heparin sulfate proteoglycans (18) . CTGF/CCN2 promotes fibroblast proliferation, ECM synthesis, cell adhesion and migration in several cell types (19) . It has been shown that CTGF/CCN2 induces ECM production in skeletal muscle both in vitro (20) and in vivo (21) . CTGF/CCN2 was reported to act downstream of transforming growth factor type-b (TGF-b) and can potentiate TGF-b pro-fibrotic effects (22, 23) . In vivo studies showed that co-injection of TGF-b and CTGF/CCN2 triggers a persistent fibrotic response for at least one week after injection (24) . Our laboratory has shown that a human monoclonal antibody against CTGF/CCN2 (FG-3019, FibroGen, Inc., San Francisco, CA, USA) reduces fibrosis and improves muscle strength in mdx mice, a murine model for Duchenne muscular dystrophy (DMD). These results were confirmed using mdxCtgf þ/-mice (25) . FG-3019 also reduces tissue remodeling and fibrosis in liver, cardiovascular system and lungs (18) . Postmortem analyses of the spinal cord from ALS patients showed that CTGF/CCN2 is up-regulated in astrocytes and motoneurons (26) . However, there is no evidence about the specific role of CTGF/CCN2 in ALS. We have recently shown that skeletal muscle from hSOD1 G93A mice exhibits fibrosis, enhanced TGF-b signaling, induction of markers of fibro/adipogenic progenitors (FAPs), together with CTGF/CCN2 up-regulation during symptomatic stages (27) . In this work, we provide evidence that the inhibition of CTGF/CCN2 activity by the FG-3019 neutralizing antibody not only reduces fibrosis, but also improves muscle and locomotor function in the hSOD1 G93A mice. Treatment with FG-3019 also reduces muscle atrophy, improves NMJ innervation and reduces myelin degeneration in the sciatic nerve. We also found that CTGF/CCN2 is expressed in astrocytes and neurons preferably in dorsal areas of spinal cord from symptomatic hSOD1 G93A mice. Thus, blocking CTGF/CCN2 activity might be a promising therapeutic approach for improving the quality of life of patients suffering from this neurodegenerative disease.
Results

CTGF/CCN2 is up-regulated in symptomatic hSOD1
G93A mice and treatment with the CTGF-blocking antibody FG-3019 improves muscle function and locomotor capacity
We previously reported that skeletal muscle of symptomatic hSOD1 G93A mice is fibrotic, with enhanced TGF-b signaling and CTGF/CCN2 up-regulation (27) . We first evaluated CTGF/CCN2 protein levels in gastrocnemius muscle from 4-, 8-, 12-and 16-week-old hSOD1 G93A mice. We observed that CTGF/CCN2 was significantly up-regulated (4-fold) in symptomatic 16-week-old hSOD1 G93A mice ( Fig. 1A and B) . It was predominantly localized at the endomysium and perimysium of skeletal muscle (Fig. 1C) .
We also determined the expression of other CCN family members and found that Ccn1 mRNA was up-regulated in the gastrocnemius from symptomatic hSOD1 G93A mice, while Ccn3 mRNA levels were down-regulated (Supplementary Material, Fig. S1A and B). To examine the role of CTGF/CCN2 in ALS progression, hSOD1 G93A mice were treated with FG-3019 (FibroGen, Inc.), which inhibits CTGF/CCN2 activity (25 mg/kg). The antibody was administered by intraperitoneal injection three times per week for 2 months, starting with 8-week-old mice ( Fig. 2A) The isometric forces of diaphragm and tibialis anterior muscles were evaluated ex-vivo to determine the effect of CTGF/ CCN2 inhibition on muscle degeneration in hSOD1 G93A mice.
Muscles from FG-3019-treated hSOD1 G93A mice generated greater specific force over a wide range of stimulation frequencies (1-200 Hz) compared with hu IgG-treated hSOD1 G93A mice ( Fig. 3A and B Fig. S2A and B) and localized predominantly at the perimysium and endomysium, as shown in Supplementary Material, Figure S2C . We found that CTGF/CCN2 co-localizes with anti-human Alexa-568 staining in consecutive gastrocnemius cross-sections, suggesting that FG-3019 localizes in the same areas as CTGF/CCN2 possibly inhibiting its activity (Supplementary Material, Fig. S2D ). We also determined that CTGF/CCN2 levels were similar in hSOD1 G93A mice treated with Figure 4A-I shows improved muscle structure, evaluated by H&E staining and immunofluorescence. We found a reduction of the interstitial space between myofibers, and of infiltrating mononuclear cells. More importantly, we found that myofibers from FG-3019-treated hSOD1 G93A mice were thicker than those from hu IgG-treated hSOD1 G93A animals, suggesting that FG-3019 treatment could reduce muscle atrophy (see below). We also found lower levels of ECM deposition, as exemplified by decreased fibronectin and collagen I levels in FG-3019-treated hSOD1 G93A mice (Fig. 4D-I ). To corroborate the reduction of ECM molecules deposition in FG-3019-treated hSOD1 G93A mice that was observed microscopically, we evaluated fibronectin protein levels by immunoblot. We found a significant reduction of fibronectin in FG-3019-treated hSOD1 G93A mice (Fig. 4J-K ).
All three TGF-b isoforms have been reported to be upregulated in skeletal muscle of hSOD1 G93A mice and ALS patients (28) . TGF-b1 and TGF-b2 are also up-regulated in spinal cord of hSOD1 G93A mice (29) , which activates the Smaddependent signaling pathway (27) . Therefore, we decided to examine whether FG-3019 inhibition of CTGF/CCN2 modulates the TGF-b signaling pathway. We evaluated TGF-b1 transcript levels, total Smad3 levels and the number of p-Smad3-positive cells in FG-3019-treated hSOD1 G93A mice. TGF-b1 mRNA levels were similarly elevated in hu IgG-treated and FG-3019-treated hSOD1 G93A mice, compared with wild-type mice. Total Smad3 protein levels and p-Smad3-positive cells were similar in FG-3019-treated and hu IgG-treated hSOD1 FG-3019 treatment reduces myofiber atrophy in hSOD1 G93A mice
The results described above ( Fig. 4A -C) suggest that CTGF/CCN2 inhibition reduces muscle atrophy in hSOD1 G93A mice. Therefore, to quantify myofiber atrophy we measured myofiber diameter in wild-type, hu IgG-treated and FG-3019-treated hSOD1 G93A mice using the minimal Feret's diameter. Figure 5A -D shows that the curve corresponding to the diameter of gastrocnemius myofibers from FG-3019-treated hSOD1 G93A mice presents a shift to the right when compared with the curve from hu IgG-treated hSOD1 G93A mice. These results indicate that mice treated with FG-3019 have thicker myofibers than hu IgG-treated mice. We also found that in FG-3019-treated hSOD1 G93A mice $30% of myofibers have a mean diameter of 30-40 mm and 10% of myofibers present a mean diameter of 10-20 mm. In contrast, $30% of myofibers in hu IgG-treated hSOD1 G93A mice have a mean diameter of 20-30mm and $25% of myofibers exhibit a 10-20 mm diameter (Fig. 5D) . Therefore, the reduction of muscle atrophy observed in FG-3019-treated hSOD1 G93A mice could be due to an improvement in nerve-muscle integrity and/or a reduction of fibrosis.
FG-3019 treatment improves NMJ innervation and reduces myelin degeneration in sciatic nerve from hSOD1 G93A mice
Denervation of skeletal muscle is one of the hallmarks of ALS that precede muscle atrophy. Since we found increased myofiber diameter in FG-3019-treated hSOD1 G93A mice, we wanted to evaluate the integrity of the nerve-muscle communication in these mice. Figure 6A -L shows neuromuscular junctions (NMJs) in diaphragms from wild-type, hu IgG-treated and FG-3019-treated hSOD1 G93A mice. Wild-type NMJs were almost totally innervated, as demonstrated by the co-localization of the stains for pre-synaptic terminals (neurofilament H and SV2) and endplates (a-bungarotoxin). In contrast, only 20% of NMJs from hu IgG-treated hSOD1 G93A mice remain innervated during the symptomatic stage (16-weeks old). Interestingly, FG-3019 treatment increases NMJs innervation from 20% to $50% as shown in Figure 6M . The reduction in myofiber atrophy and the increased NMJs innervation suggested that the loss of integrity of peripheral nerves in hSOD1 G93A mice could be ameliorated by CTGF/CCN2
inhibition. Thus, to further monitor nerve integrity in FG-3019-treated hSOD1 G93A mice, we evaluated myelin degeneration in the sciatic nerve by toluidine blue staining and electron microscopy. Figure 7A -F shows that myelin degeneration is reduced in FG-3019-treated hSOD1 G93A mice. There was less degenerated myelin structure per total myelin sheaths ( Fig. 7G ) and per area (Fig. 7H ). Figure 7I shows that there is a reduction of axon diameter in hu IgG-treated and FG-3019-treated hSOD1 G93A mice compared with wild-type animals. Notably, scatter plots show that g-ratios (ratio of axon diameter to myelin diameter) from hu IgG-treated hSOD1 G93A mice are decreased compared with g-ra-
tios from wild-type mice. However, we found that there is a slight increase of g-ratios in FG-3019-treated hSOD1 G93A mice compared with those of hu IgG-treated hSOD1 G93A mice (Fig. 7J ), suggesting that myelin thickness could be partially restored. We did not find statistically significant changes in average g-ratios for the three experimental groups (Fig. 7K) . Together with the improvement of skeletal muscle structure, our results indicate that sciatic nerve, NMJs and axons are at least partially protected from innervation and degeneration in FG-3019-treated hSOD1 G93A mice.
CTGF/CCN2 is up-regulated and predominantly located in dorsal area of spinal cord in hSOD1 G93A mice
Since we found an improvement in skeletal muscle architecture and in peripheral nerves, we asked whether CTGF/CCN2 could have a detrimental role in the spinal cord, which is characterized by neuroinflammation, a process that involved activation of microglia and astrocytes, infiltration of immune cells and high levels of inflammatory cytokines (30, 31) . Therefore, we determined CTGF/CCN2 protein levels and tested if the FG-3019 antibody was able to reach the spinal cord in hSOD1 G93A mice.
To address this question, we evaluated CTGF/CCN2 protein levels in spinal cords from 4-, 8-, 12-and 16 weeks old hSOD1 G93A mice. We found that CTGF/CCN2 levels have a tendency to increase in the early stages, and that this increase becomes statistically significant (3-fold) during the symptomatic stages of 16-week-old hSOD1 G93A mice ( Fig. 8A and B Figure S4 shows a modest CTGF/CCN2 expression in wild-type mice that co-localize with GFAP-positive cells (astrocytes) and neurons (NF-H staining). However, in spinal cord from symptomatic hSOD1 G93A mice, we found stronger fluorescence intensity for CTGF/CCN2 in both astrocytes and neurons ( Fig. 9A-J) . Moreover, we found stronger fluorescence intensity for CTGF/CCN2 in neurons (NeuN-positive) preferably in dorsal areas of the spinal cord from hSOD1 G93A mice (Fig. 9K-N) . Figure 9O shows a diagram indicating that CTGF/CCN2-postive cells within the spinal cord are predominantly in the gray matter (GM) of dorsal areas rather than ventral areas, where we found fewer CTGF/CCN2-positive cells. We also determined that CTGF/CCN2 is up-regulated not only in the lumbar area, but also in the thoracic area of the spinal cord (Fig. 9P) . Moreover, we did not find a correlation between ECM molecules and CTGF/CCN2 protein levels in the spinal cord (Fig. 9) . Thus, CTGF/CCN2 upregulation observed in spinal cord could be due to an overproduction of CTGF/CCN2 in both astrocytes and neurons located predominantly in dorsal areas of spinal cord, in where FG-3019 could be reaching and inhibits CTGF/CCN2 activity.
Discussion
In this study, we show that CTGF/CCN2 is up-regulated in both spinal cord and skeletal muscle from symptomatic hSOD1 G93A mice and that treatment with FG-3019 reduces atrophy, improves muscle architecture and strength as well as locomotor function. We also found that CTGF/CCN2 levels in spinal cord are increased in 16-week-old hSOD1 G93A mice showing a tendency to increase during pre-symptomatic stages (from 4-to 12 weeks old). Moreover, we found that CTGF/CCN2-positive cells are located predominantly in the dorsal area of spinal cord from hSOD1 G93A mice.
Little is known about the role of CTGF/CCN2 in ALS. Postmortem analyses of spinal cord from ALS patients show that CTGF/CCN2 expression is increased in this tissue (26) . Hz. Values correspond to the mean 6 S.E.M. of five animals for each experimental condition, Two-way ANOVA or t-test, *P < 0.05, **P < 0.005, ***P < 0.001.
Furthermore, we previously showed that CTGF/CCN2 protein levels are increased in gastrocnemius from symptomatic hSOD1 G93A mice (27) . Spliet et al. found CTGF/CCN2 immunoreactivity in astrocytes and motoneurons in post-mortem spinal cord from sALS and fALS patients (26) . On this regard, we found that both astrocytes (GFAP-positive cells) and neurons (NF-H and NeuN-positive cells) are probably the producers of CTGF/ CCN2 in spinal cord from symptomatic hSOD1 G93A mice.
Moreover, we observed that CTGF/CCN2 is also up-regulated in thoracic areas of the spinal cord, indicating that its detrimental effect may be not restricted to the lumbar area. We also found an increase in Ccn1 mRNA levels in both hu IgG-treated and FG-3019-treated hSOD1 G93A mice. CCN1 has also been identified as a pro-fibrotic factor after ischemic kidney injury (32) and it can enhance Smad-dependent TGF-b signaling pathway to promote lung fibrosis (33) . In contrast, we found a decrease in Ccn3 mRNA levels in both hu IgG-treated and FG-3019-treated hSOD1 G93A mice. The evidence shows that CCN3 suppresses ECM deposition acting as an anti-fibrotic factor in several cell types (34) (35) (36) . Thus, reduced levels of CCN3 in symptomatic hSOD1 G93A mice could be promoting fibrosis.
The pro-fibrotic role of CTGF/CCN2 is well-described in several tissues such as liver, kidney and skeletal muscle (21, 25, 37, 38) . However, the role of CTGF/CCN2 in the nervous system has been only partially explored to date. It has been shown that CTGF/CCN2 acts as a pro-apoptotic factor, induced by glial-derived TGF-b2, which eliminates newborn neurons in an activity-dependent manner in the mouse olfactory bulb and CTGF/CCN2 knock-down results in better odorant detection and discrimination (39) . It was shown that CTGF/CCN2 induces astrogenesis and fibronectin expression in neural progenitor cultures (40) , suggesting that CTGF/CCN2 could also be acting as an inducer of the expression of ECM molecules in the nervous system. More recently, it has been demonstrated that CTGF/ CCN2 is up-regulated in neurons that lack Tsc1 gene, which is known to trigger a hypomyelination phenotype. Even more, the authors show that genetic ablation of CTGF/CCN2 in neurons improves myelination and oligodendrocytes development, indicating that CTGF/CCN2 is a key actor for myelination in central nervous system (41) . In concordance with these results, we found that CTGF/CCN2 inhibition by FG-3019 reduces myelin degeneration in sciatic nerve of hSOD1
G93A
. However, there is no evidence showing the role of CTGF/CCN2 in myelination of the peripheral nerves. We found a decrease of g-ratios in hSOD1 G93A mice, likely due to the presence of atrophic axons with thicker myelin sheaths as consequence of axon metabolic abnormalities. Similar results have been found in a previous study (42) . We found a slightly restoration of g-ratios in FG-3019-treated hSOD1 G93A mice, suggesting that myelin thickness could be partially restored since we did not find an improvement of axon diameter. The blockade of CTGF/CCN2 activity has been studied in fibrotic chronic diseases such as liver disease (37) and nephropathy (38) . Moreover, FG-3019 treatment is able to reduce fibrosis in liver, cardiovascular system and lungs (18) . The safety and efficacy of FG-3019 have been evaluated in patients with idiopathic pulmonary fibrosis (43), diabetes and microalbuminuria (44) . Our laboratory has shown that FG-3019 treatment is able to reduce fibrosis and improve muscle architecture and strength in mdx mice (25) . In this work, we treated hSOD1 G93A mice with FG-3019 and observed several beneficial effects. The treatment with FG-3019 not only reduces fibrosis but also improves muscle and locomotor function, preventing muscle atrophy and improving NMJs innervation in hSOD1 G93A mice. We also show that FG-3019-treated hSOD1 G93A mice have reduced interstitial space between myofibers and better muscle architecture. These results are in agreement with what was previously reported on several tissues including skeletal muscle (18, 25, 45, 46) . It has been shown that CTGF/CCN2 co-localizes with the NMJ (47), suggesting a possible role in this structure. The authors proposed that CTGF/CCN2 could have an important function at the NMJ modulating Wnt signaling. However, the role of CTGF/CCN2 in NMJ maintenance has not been elucidated. Recently, it has been shown that an adeno-associated virus vector encoding DOK7, a protein that activates musclespecific kinase (MuSK), is able to suppress NMJs denervation and muscle atrophy in hSOD1 G93A mice (48) . Furthermore, the suppression of muscle atrophy observed in FG-3019-treated mice could partially be explained by an unknown role of CTGF/ CCN2 at the NMJ. In this work we also found that FG-3019 reaches the skeletal muscle and spinal cord of hSOD1 G93A mice. It has been reported that blood-brain barrier and blood-spinal cord barrier permeability is compromised at early and late stages of the disease in hSOD1 G93A mice (49) . It has also been reported that blood-spinal cord barrier is disrupted in sALS patients, probably leading to degeneration of motoneurons and progression of the disease (50) . This evidence explains why the FG-3019 antibody reaches the spinal cord in hSOD1 G93A mice, where it potentially inhibit CTGF/CCN2 activity. The observation of less myelin degeneration in the sciatic nerve suggests that disease-associated alterations in nerve-muscle communication are partially preserved in FG-3019-treated hSOD1 G93A mice. The role of CTGF/CCN2 in spinal cord is largely unexplored; however, it could be involved in the synthesis of ECM molecules and/or may have a proapoptotic effect (39, 40) . The data presented in this work indicate that CTGF/CCN2 could be a novel therapeutic target for the treatment of ALS and other neurodegenerative diseases characterized by elevated levels of ECM molecules and CTGF/CCN2 up-regulation. This therapeutic approach could ameliorate symptoms and improve the patients' quality of life. 
Materials and Methods
Animal and tissue collection
All protocols were conducted in strict accordance and with the formal approval of the Animal Ethics Committee of the Pontificia Universidad Cató lica de Chile. The hemizygous transgenic mice carrying the mutant human SOD1 G93A [B6SJL-Tg (SOD1*G93A) 1Gur/J] gene were obtained from Jackson Laboratories (Bar Harbor, USA). Wild-type (B6SJL) and hSOD1 G93A age-matched male mice were used in this study. condition. One-way ANOVA, ***P < 0.001. Scale bar corresponds to 100 mm.
Animals were anesthetized with 3.0% isoflurane gas in pure oxygen and sacrificed by cervical dislocation. Gastrocnemius, diaphragm and tibialis anterior muscles, as well as spinal cord were dissected and removed. Muscle samples for cryosectioning were frozen in liquid nitrogen cooled-isopentane (Merck, Darmstadt, GE) and stored at À80 C until processing. For spinal cord cryosections, briefly, animals were perfused with 4% paraformaldehyde and spinal cords were dissected. Spinal cords were post-fixed with 4% paraformaldehyde overnight at 4 C.
Then, spinal cords were dehydrated in 30% sucrose overnight at 4 C. Once dehydrated, spinal cords were sectioned obtaining 20 mm slices.
FG-3019 neutralizing antibody treatment
Human monoclonal IgG antibody against CTGF/CCN2 (FG-3019) and nonspecific human IgG control antibody (hu IgG) were obtained from FibroGen, Inc. Antibodies were administered intraperitoneally to 8-week-old hSOD1 G93A male mice at doses of 25 mg/kg each, three times per week for 2 months (25). After treatment, mice were sacrificed as described previously.
Disease progression analysis
Body weight was measured weekly and the onset of disease was determined by the day of maximum body weight. The experiment stopped when hu IgG-treated hSOD1 G93A mice were 16-week-old or reached end-stage, considered as the inability of a mouse to right itself within 30 s after being placed on its side (51) . The hanging test was used to evaluate muscle function. Mice were lifted by the tail, allowed to grasp the middle of the wire with their fore limbs, and then were gently lowered to let them put their hind paws on the wire. The tail was released while the mouse was grasping the wire with its four paws, and upon release, time measurement was started. The duration of time each mouse was able to hang from the wire was recorded. Every mouse had three attempts per session, with at least 1 min recovery period between attempts. The open-field test was used to measure spontaneous locomotor activity of mice. Briefly, animals were placed in an empty box (50 Â 50 cm) for 2 min to avoid stress and then their movement was recorded for 10 min. Total distance travelled (m) and average speed (m/s) were calculated using ANY-maze software (ANY-maze, Wood Dale, IL, USA).
Isometric force measurement
The isometric force of isolated tibialis anterior muscle and diaphragm was measured at optimum muscle length (L o ). Stimulation voltage was determined from micromanipulation of muscle length to produce a maximum isometric twitch force. Maximum isometric tetanic force (P o ) was determined from the plateau of the frequency-force relationship after successive stimulations at 1-200 Hz for 450 ms, with 2 min rest between the stimuli. After measurements, muscles were removed from the bath, trimmed of their tendons and of any nonmuscle tissue and weighed. Specific force or stress (force normalized per total muscle fiber cross-sectional area; mN/mm 2 ) was calculated from muscle mass and L o (25) .
Hematoxylin and eosin staining
Gastrocnemius muscle cryosections (7 mm) were placed onto glass slides. Hematoxylin and eosin staining was performed to assess muscle architecture and histology. Briefly, tissue sections were incubated for 10 min in formalin (10% v/v), then washed with water, incubated for 5 min with diluted hematoxylin (Merck, Darmstadt, GE; 25% v/v in H 2 O) and washed with water. Eosin was added for 30 s and then dehydration with ethanol was performed. Finally, Entellan (Merck, Darmstadt, GE) was added to the slices. Sections were imaged using bright field microscopy on a Nikon Eclipse E600.
Immunohistochemistry staining
Gastrocnemius muscle cryosections (7 mm) were fixed in cold ethanol, rinsed in 0.05 M TBS buffer pH 7.6, and incubated overnight with primary antibody against CTGF/CCN2 (Santa Cruz, USA). Sections were washed three times for 5 min in TBS at RT and then incubated with secondary antibody for 30 min followed by three 5 min washes with TBS. Then, sections where incubated with peroxidase-anti-peroxidase (PAP) complex (1:200) (MP Biomedicals, Aurora, OH) for 30 min, then washed in TBS (3x-5 min). The immunoperoxidase reaction was visualized after incubation of sections in 0.1% diaminobenzidine and 0.03% hydrogen peroxide for 2 min. Sections were washed with tap water and counterstained with hematoxylin, them they were dehydrated in an ethanol gradient and cleared with xylene (52).
Analysis of sciatic nerves
Sciatic nerves were extracted and subjected to toluidine blue staining and EM (electron microscopy). For EM, sciatic nerves were fixed overnight with 2.5% glutaraldehyde, 0.01% picric acid and 0.05 M cacodylate buffer, pH 7.3. Sciatic nerves were incubated in the same buffer with 1% OsO 4 and then immersed in 2% uranyl acetate, dehydrated in an ethanol/acetone gradient and infiltrated in Epon (Ted Pella) as described previously (53, 54) . Thin sections (80 nm) were obtained and mounted in copper grids and contrasted using 1% uranyl acetate and lead citrate. Observations were made using a Phillips Tecai 12 transmission electron microscope (Eindhoven) at 80 kV and photographed by a Mega view G2 camera (Olympus). For axon diameter analysis, at least 100 fibers were analyzed in three different areas in all animal using ImageJ software (NIH, USA). (27) . For nuclear staining, sections were incubated with 1 mg/ml Hoechst 33258 for 10 min. For spinal cord immunofluorescence, cryosections were washed three times with PBS for 10 min, permeabilized/blocked with 1% BSA. 0.3% Triton X-100 in PBS for 30 min and incubated with the corresponding antibodies as described above. For NMJ staining, briefly, diaphragms were dissected from mice and immediately fixed in 4% PFA for 30 min. Then, they were incubated with a-bungarotoxin (a-BTX; 5mg/mL; Thermo Fisher, Waltham, MA, USA; to stain end-plates) for 30 min at room temperature and blocked 1 h with 1% BSA, 0, 4% lysine; 0, 5% Triton X-100 in PBS. Diaphragms were subjected to immunofluorescence using anti-neurofilament H and anti-SV2 (to stain pre-synaptic terminals) as described previously (55) . Slices were then washed in water and mounted in fluorescent mounting medium (DAKO). Sections were visualized on a Nikon Eclipse E600 epifluorescence microscope or a Nikon Eclipse C2 si confocal spectral microscope using NIS-Elements software v4.20, 32 bit.
Immunofluorescence microscopy
Immunoblot analysis
Skeletal muscles were homogenized in 10 volumes of Tris-EDTA buffer pH 7.4 with 1 mM phenylmethylsulfonyl fluoride (PMSF). Then, one volume of buffer containing 2% glycerol, 4% SDS and 0.125 M Tris pH 6.8 were added to the homogenates. Spinal cords were homogenized in 10 volumes of RIPA 1Â buffer (Cell Signaling) with 1 mM PMSF. Protein concentration was determined in aliquots of muscle extracts using the Bicinchoninic Acid Protein Assay kit (Pierce, Rockford, IL, USA) with BSA as the standard. Aliquots (40-50 mg) were subjected to sodium dodecyl sulfate gel electrophoresis (SDS-PAGE) in 9% polyacrylamide gels, electrophoretically transferred onto PVDF membranes (Millipore) and probed with the following antibodies at 4 C overnight: anti-fibronectin (Sigma-Aldrich),
anti-Smad3 (Cell Signaling), anti-CTGF/CCN2 (Santa Cruz, USA), anti-GAPDH (Millipore) or anti-a-tubulin (SigmaAldrich). Following incubation for 1 h at room temperature, primary antibodies were detected with horseradish-peroxidaseconjugated secondary antibodies or horseradish-peroxidaseconjugated anti-human secondary antibody for FG-3019 detection. All immunoreactions were visualized by enhanced chemiluminescence (Pierce). Densitometric analysis and quantification were performed using the ImageJ software (NIH).
RNA isolation, reverse transcription and quantitative real-time PCR
Total RNA was isolated from gastrocnemius muscle using TRIzol (Invitrogen) according to the manufacturer's instructions. Total RNA (2 mg) was reverse transcribed into cDNA using random primers and M-MLV reverse transcriptase (Invitrogen that was used as a reference gene for Cnn1 and Ccn3. mRNA expression was quantified with the comparative DCt method (2-DDCt), using GAPDH as reference gene. The mRNA levels were expressed relative to the mean expression in wild-type mice.
Determination of fiber diameter
Fresh-frozen gastrocnemius muscles were cryosectioned (7 mm) and placed on glass slides, fixed in 4% paraformaldehyde (Merck) and subjected to immunofluorescence using an antilaminin antibody, as described previously. Fiber size was calculated using the ImageJ software (NIH) on reconstructed images of each gastrocnemius muscle. Fibers were manually selected and the minimal Feret diameter of each fiber was computed by the software.
Statistical analyses
The statistical significance of the differences between the means of the experimental groups was evaluated using oneway ANOVA or two-way ANOVA when appropriate. For multiple comparisons, a post-hoc Bonferroni test was performed. A difference was considered statistically significant with a P-value < 0.05. All data analyses and statistical analyses were performed using the Prism 5 software (Graph Pad Software, CA, USA).
Supplementary Material
Supplementary Material is available at HMG online. 
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